Breast Cancer Excellence Forum

Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Seth Wander, MD, PhD, Massachusetts General Hospital

Videos

Novel Endocrine Agents for Patients With HR-Positive Breast Cancer

05/08/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...

At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Denise Yardley, MD, Sarah Cannon Research Institute

Videos

Is Age 50 Relevant for Decisions in Early HR-Positive Breast Cancer?

05/08/2024

Featuring Denise Yardley, MD

At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center

Videos

Sequential Antibody Drug Conjugates for Patients With Metastatic Breast Cancer

05/08/2024

Featuring Neil Iyengar, MD

At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Videos

Pertuzumab Plus Trastuzumab for Early-Stage HER2-Positive Breast Cancer

02/22/2024

Reshma Mahtani , DO;

Terry Mamounas , MD;

Jane Meisel , MD;

In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.

In this video, a panel of...

02/22/2024

Oncology

Videos

Optimizing Treatment for Patients With High-Risk HER2-Positive Breast Cancer

02/21/2024

Reshma Mahtani , DO;

Terry Mamounas , MD;

Jane Meisel , MD;

In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...

In this video, our experts...

02/21/2024

Oncology

Videos

Managing Patients With Stage 1 HER2-Positive Breast Cancer

02/21/2024

Reshma Mahtani , DO;

Terry Mamounas , MD;

Jane Meisel , MD;

In this video, a panel of experts discuss the management of patients with stage 1, HER2-positive breast cancer, sharing data from several trials in this space, including the APT, ADEPT, and ATEMPT 2.0 trials.

In this video, a panel of...

02/21/2024

Oncology

Videos

Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer

02/15/2024

In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...

In this video, a panel of...

02/15/2024

Oncology

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Considerations for Endocrine Therapy for Patients With ER-Positive Early Breast Cancer

12/12/2023

Seth Wander , MD;

Cynthia Ma , MD;

Neelima Vidula , MD;

Cynthia Ma, MD, leads part 4 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for endocrine therapy for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 4 of...

12/12/2023

Oncology

Videos

Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer

12/12/2023

Cynthia Ma , MD;

Neelima Vidula , MD;

Seth Wander , MD;

Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 3 of...

12/12/2023

Oncology

Videos

Response to Short Preoperative Endocrine Therapy Among Patients With HR-Positive, HER2-Negative Breast Cancer

12/08/2023

Oleg Gluz , MD;

Oleg Gluz, MD, shares results from the screening cohort of the phase 3 ADAPTcycle trial.

Oleg Gluz, MD, shares results...

12/08/2023

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology